This Plain Language Summary of Publication article (PLSP) from Future Oncology evaluated erdafitinib against chemotherapy in patients with advanced or metastatic urothelial cancer (bladder and upper/lower tract cancer). The study specifically focused on patients whose cancers had FGFR2 or FGFR3 genetic alterations and had progressed despite one or two previous treatments including immunotherapy. The research aimed to determine if erdafitinib could safely and effectively extend survival for these patients, addressing the critical need for additional treatment options following immunotherapy failure.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.